4AZ3

crystal structure of cathepsin a, complexed with 15a


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.04 Å
  • R-Value Free: 0.215 
  • R-Value Work: 0.188 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Novel Beta-Amino Acid Derivatives as Inhibitors of Cathepsin A.

Ruf, S.Buning, C.Schreuder, H.Horstick, G.Linz, W.Olpp, T.Pernerstorfer, J.Hiss, K.Kroll, K.Kannt, A.Kohlmann, M.Linz, D.Hubschle, T.Rutten, H.Wirth, K.Schmidt, T.Sadowski, T.

(2012) J.Med.Chem. 55: 7636

  • DOI: 10.1021/jm300663n
  • Primary Citation of Related Structures:  
  • Also Cited By: 4CIB, 4CIA, 4CI9

  • PubMed Abstract: 
  • Cathepsin A (CatA) is a serine carboxypeptidase distributed between lysosomes, cell membrane, and extracellular space. Several peptide hormones including bradykinin and angiotensin I have been described as substrates. Therefore, the inhibition of Cat ...

    Cathepsin A (CatA) is a serine carboxypeptidase distributed between lysosomes, cell membrane, and extracellular space. Several peptide hormones including bradykinin and angiotensin I have been described as substrates. Therefore, the inhibition of CatA has the potential for beneficial effects in cardiovascular diseases. Pharmacological inhibition of CatA by the natural product ebelactone B increased renal bradykinin levels and prevented the development of salt-induced hypertension. However, so far no small molecule inhibitors of CatA with oral bioavailability have been described to allow further pharmacological profiling. In our work we identified novel β-amino acid derivatives as inhibitors of CatA after a HTS analysis based on a project adapted fragment approach. The new inhibitors showed beneficial ADME and pharmacokinetic profiles, and their binding modes were established by X-ray crystallography. Further investigations led to the identification of a hitherto unknown pathophysiological role of CatA in cardiac hypertrophy. One of our inhibitors is currently undergoing phase I clinical trials.


    Organizational Affiliation

    Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany. sven.ruf@sanofi.com




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
LYSOSOMAL PROTECTIVE PROTEIN 32 KDA CHAIN
A
300Homo sapiensMutation(s): 0 
Gene Names: CTSA (PPGB)
EC: 3.4.16.5
Find proteins for P10619 (Homo sapiens)
Go to Gene View: CTSA
Go to UniProtKB:  P10619
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
LYSOSOMAL PROTECTIVE PROTEIN 20 KDA CHAIN
B
155Homo sapiensMutation(s): 0 
Gene Names: CTSA (PPGB)
EC: 3.4.16.5
Find proteins for P10619 (Homo sapiens)
Go to Gene View: CTSA
Go to UniProtKB:  P10619
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
S35
Query on S35

Download SDF File 
Download CCD File 
A
(3S)-3-({[1-(2-fluorophenyl)-5-{[(2R)-2-hydroxy-3,3-dimethylbutyl]oxy}-1H-pyrazol-3-yl]carbonyl}amino)-3-(2-methylphenyl)propanoic acid
C26 H30 F N3 O5
PUJVTKSRQZHCAT-UGKGYDQZSA-N
 Ligand Interaction
NAG
Query on NAG

Download SDF File 
Download CCD File 
A
N-ACETYL-D-GLUCOSAMINE
C8 H15 N O6
OVRNDRQMDRJTHS-FMDGEEDCSA-N
 Ligand Interaction
CD
Query on CD

Download SDF File 
Download CCD File 
A, B
CADMIUM ION
Cd
WLZRMCYVCSSEQC-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
S35IC50: 5 nM (100) BINDINGDB
S35IC50: 5 nM BINDINGMOAD
S35IC50: 5 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.04 Å
  • R-Value Free: 0.215 
  • R-Value Work: 0.188 
  • Space Group: C 1 2 1
Unit Cell:
Length (Å)Angle (°)
a = 90.590α = 90.00
b = 102.800β = 101.87
c = 48.390γ = 90.00
Software Package:
Software NamePurpose
XSCALEdata scaling
BUSTERrefinement
XDSdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2012-09-26
    Type: Initial release